Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × zipalertinib × 1 year × Clear all

Phase

Phase 3 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lung Diseases 1 Carcinoma 1

Interventions

pembrolizumab 462 Carboplatin 329 Specimen Handling 325 Cisplatin 288 Magnetic Resonance Spectroscopy 287 Nivolumab 273 Cyclophosphamide 260 Paclitaxel 230 Radiotherapy 217 Biopsy 200 Gemcitabine 191 Bevacizumab 183 Dexamethasone 151 durvalumab 146 Rituximab 144 atezolizumab 138 Capecitabine 138 Oxaliplatin 136 Docetaxel 135 Fluorouracil 133 venetoclax 131 Ipilimumab 121 Etoposide 120 Drug Therapy 120 Doxorubicin 113 Prednisone 111 Lenalidomide 109 Radiosurgery 104 Pemetrexed 98 Leucovorin 98

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05967689 2026-03-10

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting

Carcinoma, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡